SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Talk to Advisor
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

Saroja Pharma Industries India Ltd (SAROJA)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: SAROJA Pharmaceuticals & Drugs | Small Cap | Saroja Pharma Ind Share Price

BSE Share Price
Not Listed

Saroja Pharma Industries India Ltd (SAROJA)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: SAROJA Pharmaceuticals & Drugs | Small Cap | Saroja Pharma Ind Share Price

BSE Share Price
Not Listed
Key Metrics
Valuation Multiples
Market Cap
₹13 Cr.
Current Price
₹0
52-Week Low / High
₹0 / 0
TTM EPS
₹4
TTM Sales
₹70.1 Cr.
Book Value per Share
₹39
P/E Ratio
8.08
Lower than its 5-year historical median
Industry PE
46.5
Price to Book (P/B)
0.83
Lower than its 5-year historical median
Price to Sales (P/S)
0.19
Lower than its 5-year historical median
EV/EBITDA
5.83
Lower than its 5-year historical median
Dividend Yield
0.00%
Profitability Efficiency
Return on Equity (ROE)
6.82%
Underperforms industry median
Return on Capital Employed (ROCE)
12.56%
Outperforms industry median
Return on Assets (ROA)
3.13%
Operating Profit Margin
5.2%
Net Profit Margin
1.92%
Gross Profit Margin
2.9%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
32.11%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
8.98%
Net Profit Growth (1 Year)
Improving versus 3-year growth rate
17.05%
Asset Quality
Promoter Holding
73.02%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹12 Cr.
Equity
₹4 Cr.
Face Value
₹10
All Time Low / High
- / -

Saroja Pharma Industries India stock performance

Key Ratios
mw4me loader

Check Before You Invest

Check Before You Invest

M-Cap below 100cr DeciZen not available

Q.1 Is Saroja Pharma Industries India Ltd a good quality company?
Saroja Pharma Industries India Ltd is a quality company, based on a multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

View More

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

View More
How does Saroja Pharma Industries India Ltd performance compare with that of its Peers?
Q.1 Revenue growth of Saroja Pharma Industries India Ltd vs industry peers?
Saroja Pharma Industries India Ltd revenue CAGR is 0.00%, compared to the industry median CAGR of 5.35%, indicating slower growth and losing its market share.
Q.1 Promoter shareholding and pledge status of Saroja Pharma Industries India Ltd?
Promoters hold 73.02% of the Saroja Pharma Industries India Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Q.1 Stock return of Saroja Pharma Industries India Ltd over the last decade?
Over the last 1 year(s), the stock has delivered a CAGR of -26.67% based on the current price.
View More

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Saroja Pharma Industries India Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation ⓘ

Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % ⓘ34.6%33.7%22.1%14.9%12.6%-
Value Creation
Index ⓘ		1.51.40.60.1-0.1-

Growth Parameters ⓘ
Sales ⓘ36.755.650.240.753.770
Sales YoY Gr.-51.8%-9.8%-19%32.1%-
Adj EPS ⓘ55.63.53.42.12.54
YoY Gr.--93.7%-2.9%-37.2%14.5%-
BVPS (₹) ⓘ7213.717.336.43939
Adj Net
Profit ⓘ		0.7110.912
Cash Flow from Ops. ⓘ-1.1-3.72.211.2-
Debt/CF from Ops. ⓘ-2.9-1.74.75.68.2-

CAGR ⓘ

9 Years 5 Years 3 Years 1 Years
Sales ⓘNANA-1.2%32.1%
Adj EPS ⓘNANA-11.3%14.5%
BVPSⓘNANA41.6%7.1%
Share Price - - - -14.9%

Key Financial Parameters ⓘ

Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity % ⓘ		77.341.5228.76.510.3
Op. Profit
Mgn % ⓘ		3.63.85.46.35.2NAN
Net Profit
Mgn % ⓘ		21.922.11.82.3
Debt to
Equity ⓘ		3.21.520.40.6-
Working Cap
Days ⓘ		0751151541530
Cash Conv.
Cycle ⓘ		0416781770

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'21Mar'22Mar'23Mar'24Mar'25
Sales36.6655.6350.1940.6753.73
Operating Expenses ⓘ + 35.3653.5347.4738.1150.94
Manufacturing Costs1.331.861.031.671.52
Material Costs32.0248.5044.313447.09
Employee Cost 0.550.730.830.920.74
Other Costs ⓘ 1.472.441.311.521.59
Operating Profit ⓘ 1.302.102.722.562.79
Operating Profit Margin (%) 3.6%3.8%5.4%6.3%5.2%
Other Income ⓘ + 0.090.320.160.190.19
Exceptional Items ⓘ 00000
Interest ⓘ 0.330.801.321.451.41
Depreciation ⓘ 0.020.050.070.090.11
Profit Before Tax ⓘ 1.041.581.491.211.45
Tax ⓘ 0.300.440.430.330.42
Profit After Tax 0.731.141.060.881.03
PAT Margin (%) 2.0%2.1%2.1%2.2%1.9%
Adjusted EPS (₹)56.33.93.62.22.6
Dividend Payout Ratio (%)0%0%0%0%0%

Valuation of Saroja Pharma Ind - Standalone

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund + 0.944.035.0914.6415.68
Share Capital ⓘ 0.010.232.944.024.02
Reserves ⓘ 0.933.802.1510.6211.66
Debt +3.026.1410.195.749.46
Long Term Debt1.421.702.812.621.38
Short Term Debt1.604.447.383.118.08
Minority Interest00000
Trade Payables4.155.315.865.6113.65
Others Liabilities ⓘ 0.120.040.200.580.77
Total Liabilities ⓘ 8.2215.5121.3426.5639.55

Fixed Assets

Net Fixed Assets ⓘ +0.090.342.222.512.51
Gross Block0.120.422.362.752.86
Accumulated Depreciation0.030.070.140.230.35
CWIP ⓘ 001.796.138.61
Investments ⓘ 00.040.140.200.34
Inventories0.660.473.870.400.10
Trade Receivables7.2213.9811.1116.2426.58
Cash Equivalents 00.260.360.320.33
Others Assets ⓘ 0.250.421.860.761.08
Total Assets ⓘ 8.2215.5121.3426.5639.55

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity ⓘ + -1.05-3.672.191.021.15
PBT ⓘ 1.041.581.491.211.45
Adjustment ⓘ 0.350.841.371.521.49
Changes in Working Capital ⓘ -2.13-5.65-0.25-1.37-1.37
Tax Paid ⓘ -0.30-0.44-0.42-0.33-0.42
Cash Flow From Investing Activity ⓘ + -0.05-0.34-4.82-4.76-2.70
Capex -0.05-0.30-3.73-0.39-0.11
Net Investments 0-0.04-0.10-0.06-0.14
Others ⓘ 00-1-4.31-2.45
Cash Flow From Financing Activity ⓘ + 1.034.272.733.701.56
Net Proceeds from Shares ⓘ 01.9508.680
Net Proceeds from Borrowing ⓘ 001.11-0.19-1.24
Interest Paid ⓘ -0.33-0.80-1.32-1.45-1.41
Dividend Paid ⓘ 00000
Others ⓘ 1.363.122.94-3.344.21
Net Cash Flow ⓘ -0.070.260.10-0.040.01

Financial Ratio

PARTICULARSMar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)78.1445.9523.288.96.82
ROCE (%)34.5933.7322.114.9112.56
Asset Turnover Ratio4.464.692.721.71.63
PAT to CFO Conversion(x)-1.44-3.222.071.161.12
Working Capital Days
Receivable Days71.9069.6091.20122.70145.50
Inventory Days6.503.7015.8019.101.70
Payable Days47.3035.604661.6074.60

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Saroja Pharma Industries India Ltd FAQs

The current trading price of Saroja Pharma Ind on 01-Jan-1970 05:30 is ₹0.00.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Saroja Pharma Ind stood at ₹13.07 Cr

The latest P/E ratio of Saroja Pharma Ind as of 31-Dec-1969 is 8.08.

The latest P/B ratio of Saroja Pharma Ind as of 31-Dec-1969 is 0.83.

The 52-week high of Saroja Pharma Ind is ₹0.00 and the 52-week low is ₹0.00.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Saroja Pharma Ind is ₹70.13 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Saroja Pharma Industries India Ltd is a average quality company.

The key valuation ratios of Saroja Pharma Industries India Ltd's currently when compared to its past seem to suggest it is in the Undervalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Saroja Pharma Industries India Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

About Saroja Pharma Industries India Ltd

Saroja Pharma Industries India was originally incorporated as Private Limited, under the Companies Act, 2013 (Companies Act) in the name and style of ‘Saroja Pharma Industries India Private Limited’ on January 14, 2019 under the provisions of the Companies Act, 2013 vide Certificate of Incorporation issued by the Registrar of Companies, Mumbai, Maharashtra. Later on, company was converted into public limited company and due to the conversion, the name of the company name was changed to ‘Saroja Pharma Industries India Limited’ and a fresh Certificate of Incorporation dated April 18, 2023 was issued by the Registrar of Companies, Mumbai, Maharashtra.

The company is amongst the leading traders, exporter and suppliers of Specialty Chemicals. The offered range is widely praised for its superior effectiveness, shelf life and perfect composition. The company was incorporated with the objective of the best service deliverance in chemical trading with the best premium pharmaceutical companies in India and abroad for cost effective human and veterinary medicine. The company trade in Pharma API, Pharma Intermediates, Chemicals, Solvents used for pharmaceutical products human and veterinary medicine. The Company was formed with a mission being providing clientele specification based approved product at a competitive pricing with hassle free dispatch within India or aboard contributing to cost effectiveness in end product for human and veterinary medicine.

The product demand by its clientele is manufactured as per their specifications by its suppliers initially in sample size thereafter on clients testing and approving the order is finalized. The approved specified product is manufactured for the order quantity to be dispatched by the appropriate mode of transport within India or abroad. Since its inception, Saroja Pharma Industries India has witnessed a substantial expansion in its clientele base over the past two years. This growth has propelled the company to venture into the manufacturing of API Pharma products, for veterinary use. By broadening its product portfolio, Saroja Pharma Industries India aims to provide a comprehensive range of pharmaceutical solutions that cater to the diverse needs of its expanding customer base. This strategic move not only enhances the company's value proposition but also reinforces its commitment to delivering affordable healthcare solutions globally.

Business area of the company 

The company is engaged into the business of trading of pharma products like pharma API, Pharma Intermediary and Pharma chemicals.

Products of the company 

Chemical

  • Liquid bromine 
  • Ethyl acetate 
  • Thionyl chloride 
  • Para nitro phenol 
  • Toluene N.G 
  • Benzyl chloride

Active Pharmaceutical Ingredient (API)

  • Oxyclozanide BP Vet
  • Bromhexine HCL BP Grade
  • Triclabendazole
  • Fenbendazole BP Vet
  • Nitroxynil BP Vet
  • Oxfendazole BP Vet
  • Albendazole USP
  • Rafoxanide BP Vet
  • Febantel EP

Pharma Intermediary

History and milestones 

  • 2019: Incorporation of the company viz. Saroja Pharma Industries India Private Limited.
  • 2023: Conversion of the company’s status from Private Limited to Limited Company to Saroja Pharma Industries India Limited. 

You have 0 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×